aspirin has been researched along with Complications of Diabetes Mellitus in 275 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear." | 9.27 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018) |
| "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study is an international double-blind, randomized controlled trial designed to investigate the superiority of the specific TP receptor antagonist terutroban (30 mg/day) over aspirin (100 mg/day), in reducing cerebrovascular and cardiovascular events in patients with a recent history of ischemic stroke or transient ischemic attack." | 9.14 | The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, HP; Rothwell, PM, 2009) |
| "To examine the impact of prognostic factors on the outcome of treatment with warfarin or aspirin after acute myocardial infarction." | 9.13 | Less benefit from warfarin in diabetics after myocardial infarction? ( Abdelnoor, M; Arnesen, H; Hurlen, M; Smith, PJ, 2008) |
| "Antiplatelet therapy with aspirin and systematic anticoagulation with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone." | 9.08 | Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. ( , 1997) |
| "To assess whether the use of aspirin exacerbates the severity or duration of vitreous/preretinal hemorrhages in patients with diabetic retinopathy." | 9.08 | Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. ( Chew, EY; Ferris, FL; Klein, ML; Murphy, RP; Remaley, NA, 1995) |
| "The Early Treatment Diabetic Retinopathy Study, a randomized clinical trial supported by the National Eye Institute, was designed to assess the effect of photocoagulation and aspirin in 3711 patients with mild to severe nonproliferative or early proliferative diabetic retinopathy." | 9.07 | Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16. ( Barton, FB; Burton, TC; Chew, EY; Ferris, FL; Remaley, NA; Williams, GA, 1992) |
| "To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly." | 9.05 | Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 9.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| "The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk." | 9.01 | Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019) |
| " The currently available antiplatelet drugs used to prevent vascular events in patients with cardiovascular disease, including peripheral arterial disease (PAD), include aspirin and thienopyridines such as clopidogrel." | 8.86 | [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010) |
| "Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases." | 8.83 | [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. ( Legrand, DA; Scheen, AJ, 2006) |
| "To evaluate whether aspirin can reduce the risk of colorectal cancer in people with diabetes." | 7.81 | Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. ( Lai, MS; Lin, CC; Shau, WY, 2015) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 7.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| " Additional subgroup analysis included the presence of hypertension, diabetes, low-density lipoprotein levels, sex, and use of aspirin." | 7.79 | Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study. ( El-Charabaty, E; El-Sayegh, S; Saifan, C, 2013) |
| "Long-term administration of low-dose aspirin (LDA) is associated with a greater risk of adverse events, including gastroduodenal ulcers." | 7.79 | Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers. ( Funaki, Y; Iida, A; Ito, Y; Kasugai, K; Kawamura, N; Mizuno, M; Ogasawara, N; Sasaki, M, 2013) |
| "In this retrospective observational study including women with pre-existing hypertension, pre-gestational diabetes or previous placental-mediated complications, we compared the rates of pre-eclampsia, early-onset and severe pre-eclampsia between women who used 81 mg of aspirin (ASA) throughout pregnancy without platelet function analyser (PFA-100®) monitoring ("group ASA no PFA") and those in whom the aspirin dosage was adjusted according to PFA-100® results ("group ASA and PFA")." | 7.77 | Is testing for aspirin response worthwhile in high-risk pregnancy? ( Rey, E; Rivard, GE, 2011) |
| "To investigate the effect of a combination of carnosine and aspirin eye drops on the progression of diabetic cataract formation induced by streptozotocin (STZ)." | 7.75 | Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats. ( Harding, JJ; Li, MY; Shi, Q; Yan, H, 2009) |
| "635 Non ST Elevation Acute Coronary Syndrome (NSTE ACS) patients were included and received loading doses of 250 mg aspirin and 600 mg clopidogrel." | 7.75 | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. ( Alessi, MC; Bali, L; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2009) |
| "Aspirin for the primary prevention of coronary heart disease (has a more favorable risk/benefit profile among adults with high coronary heart disease risk than among low-risk adults, but there is little information on the current patterns of aspirin use for primary prevention." | 7.73 | Aspirin use for the primary prevention of coronary heart disease in older adults. ( Bauer, DC; Butler, J; Cornuz, J; Ding, J; Harris, TB; Hulley, SB; Newman, AB; Rodondi, N; Satterfield, S; Vittinghoff, E, 2005) |
| "The results of a case-control study of 300 cataract patients and 609 controls indicate that long-term use of aspirin-like analgesics halves the risk of cataract." | 7.67 | Do aspirin-like analgesics protect against cataract? A case-control study. ( Harding, JJ; van Heyningen, R, 1986) |
| "The prevalence of cataracts is significantly lower in patients with rheumatoid arthritis receiving aspirin (mean of 2,700 mgs daily for an average of 10." | 7.66 | Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes. ( Cotlier, E, 1981) |
| "CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0." | 6.80 | The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. ( Gregersen, S; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2015) |
| "Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy." | 6.74 | Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 6.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| " All patients were randomly assigned to take aspirin 75 mg/day or placebo, and patients in the aspirin group had a 15% lower rate of major cardiovascular events and myocardial infarctions than did patients who received placebo." | 6.19 | Aggressive blood pressure lowering is safe, but benefit is still hard to prove. ( Pohl, MA; Vidt, DG, 1999) |
| " Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear." | 5.27 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018) |
| " In the uncommon occurrence of asthma and diabetes in the same patient, insulin dosage should be considered as a factor in all such asthmatics who do not respond well to conventional therapy." | 5.26 | Diabetes mellitus and insulin in an aspirin sensitive asthmatic. ( Caplin, I, 1976) |
| "The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study is an international double-blind, randomized controlled trial designed to investigate the superiority of the specific TP receptor antagonist terutroban (30 mg/day) over aspirin (100 mg/day), in reducing cerebrovascular and cardiovascular events in patients with a recent history of ischemic stroke or transient ischemic attack." | 5.14 | The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, HP; Rothwell, PM, 2009) |
| "To examine the impact of prognostic factors on the outcome of treatment with warfarin or aspirin after acute myocardial infarction." | 5.13 | Less benefit from warfarin in diabetics after myocardial infarction? ( Abdelnoor, M; Arnesen, H; Hurlen, M; Smith, PJ, 2008) |
| "Although aspirin has no significant risk on primary endpoints of cardiovascular events and bleeding outcomes in patients with diabetes compared to control, major adverse cardiovascular events (MACE) were significantly lower in the aspirin group." | 5.12 | Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. ( Gu, Q; Li, X; Ma, H; Niu, H; Wang, R, 2021) |
| "Antiplatelet therapy with aspirin and systematic anticoagulation with warfarin reduce cardiovascular morbidity and mortality after myocardial infarction when given alone." | 5.08 | Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. ( , 1997) |
| "To assess whether the use of aspirin exacerbates the severity or duration of vitreous/preretinal hemorrhages in patients with diabetic retinopathy." | 5.08 | Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. ( Chew, EY; Ferris, FL; Klein, ML; Murphy, RP; Remaley, NA, 1995) |
| "Indobufen--an inhibitor of platelets aggregation--has been used in 306 patients with intermittent claudication due to peripheral vascular disease." | 5.07 | Long-term evaluation of indobufen in peripheral vascular disease. ( Belcaro, G; De Simone, P, 1991) |
| "The Early Treatment Diabetic Retinopathy Study, a randomized clinical trial supported by the National Eye Institute, was designed to assess the effect of photocoagulation and aspirin in 3711 patients with mild to severe nonproliferative or early proliferative diabetic retinopathy." | 5.07 | Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16. ( Barton, FB; Burton, TC; Chew, EY; Ferris, FL; Remaley, NA; Williams, GA, 1992) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 5.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| "To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly." | 5.05 | Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020) |
| "The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk." | 5.01 | Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019) |
| "A literature search was conducted using the terms cardiovascular disease, aspirin, diabetes mellitus to identify trials of patients with diabetes who received aspirin for primary prevention of CVD." | 4.93 | Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis. ( Berlie, HD; Garwood, CL; Kokoska, LA; Wilhelm, SM, 2016) |
| " In absolute terms, these relative risks indicate that for every 10,000 diabetic patients treated with aspirin, 109 MACE may be prevented at the expense of 19 major bleeding events (with the caveat that the relative risk for the latter is not statistically significant)." | 4.87 | Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. ( Butalia, S; Ghali, WA; Leung, AA; Rabi, DM, 2011) |
| " The currently available antiplatelet drugs used to prevent vascular events in patients with cardiovascular disease, including peripheral arterial disease (PAD), include aspirin and thienopyridines such as clopidogrel." | 4.86 | [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010) |
| " Based on this concept, we have performed several large-scale clinical trials to provide EBM, including the Japanese Antiplatelets Myocardial Infarction Study [JAMIS; clinical improvement in acute myocardial infarction (AMI) patients with antiplatelet therapy], the Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI; comparison of the effects of beta-blockers and calcium antagonists on cardiovascular events in post-AMI patients), a multicenter study for aggressive lipid-lowering strategy by HMG-CoA reductase inhibitors in patients with AMI (MUSASHI; effects of statin therapy on cardiovascular events in patients with AMI), and the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD trial; efficacy of low-dose aspirin therapy for primary prevention of atherosclerotic events in type 2 diabetic patients)." | 4.85 | Clinical evidence for Japanese population based on prospective studies--linking clinical trials and clinical practice. ( Kojima, S; Ogawa, H, 2009) |
| "Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases." | 4.83 | [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. ( Legrand, DA; Scheen, AJ, 2006) |
| " Association of bronchial asthma, nasal pathology and intolerance to aspirin is a unique syndrome." | 4.75 | Aspirin intolerance--a review. ( Abrishami, MA; Thomas, J, 1977) |
| " In a cross-sectional study of 787 patients with newly diagnosed clinical stage IB or II melanoma, we estimated odds ratios for the association of proinflammatory factors (high body mass index, diabetes, cardiovascular disease, hypertension, and smoking) or the use of anti-inflammatory medications (statins, aspirin, corticosteroids, and nonsteroidal anti-inflammatory drugs), with ulcerated primary melanoma using regression models and subgroup analyses to control for melanoma thickness and mitotic rate." | 3.85 | Associations of Statins and Diabetes with Diagnosis of Ulcerated Cutaneous Melanoma. ( Green, AC; Hughes, MCB; Khosrotehrani, K; Malt, M; Smith, D; Smithers, BM; van der Pols, JC; von Schuckmann, LA, 2017) |
| "To evaluate whether aspirin can reduce the risk of colorectal cancer in people with diabetes." | 3.81 | Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. ( Lai, MS; Lin, CC; Shau, WY, 2015) |
| "The effects of dual antiplatelet therapy with aspirin and clopidogrel on the progression of native coronary artery disease after coronary artery bypass grafting are unknown." | 3.80 | Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial. ( Al-Atassi, T; Kulik, A; Le May, M; Ruel, M; Une, D; Voisine, P, 2014) |
| " This adherence was concerned particularly with co-medication in patients diagnosed with hypertension, aspirin prescription in elderly patients and the achievement of target lipid levels following the prescription of statins." | 3.79 | Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study. ( Hintersteiner, J; Johnson, J; Kamyar, MR; Kautzky, A; Kautzky-Willer, A; Lemmens-Gruber, R; Saukel, J; Stich, K, 2013) |
| "Long-term administration of low-dose aspirin (LDA) is associated with a greater risk of adverse events, including gastroduodenal ulcers." | 3.79 | Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers. ( Funaki, Y; Iida, A; Ito, Y; Kasugai, K; Kawamura, N; Mizuno, M; Ogasawara, N; Sasaki, M, 2013) |
| " Additional subgroup analysis included the presence of hypertension, diabetes, low-density lipoprotein levels, sex, and use of aspirin." | 3.79 | Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study. ( El-Charabaty, E; El-Sayegh, S; Saifan, C, 2013) |
| " Old age, bilateral diverticulosis, presence of atherosclerosis related diseases (hypertension, diabetes mellitus, ischemic heart disease, obesity), use of aspirin, NSAIDs and calcium channel blocker, increased the risk of bleeding." | 3.78 | [The risk factors for colonic diverticular bleeding]. ( Hwang, JH; Jeong, SH; Jo, HJ; Jung, HC; Kim, HY; Kim, JW; Kim, N; Lee, DH; Lee, SH; Park, H; Park, YS; Seo, PJ; Shin, CM; Song, IS; Suh, S, 2012) |
| " Data were analysed from three community-dwelling populations of older persons (>50 years) in central Scotland: the Aspirin for Asymptomatic Atherosclerosis (AAA) Trial (n = 2,091), the Edinburgh Type 2 Diabetes Study (ET2DS, n = 1,066), and the Lothian Birth Cohort 1936 (LBC1936, n = 1,091)." | 3.77 | Genetic associations between fibrinogen and cognitive performance in three Scottish cohorts. ( Deary, IJ; Fowkes, FG; Gow, AJ; Harris, SE; Houlihan, LM; Lowe, GD; Luciano, M; Marioni, RE; Murray, GD; Price, JF; Rumley, A; Stewart, MC; Strachan, MW, 2011) |
| "In this retrospective observational study including women with pre-existing hypertension, pre-gestational diabetes or previous placental-mediated complications, we compared the rates of pre-eclampsia, early-onset and severe pre-eclampsia between women who used 81 mg of aspirin (ASA) throughout pregnancy without platelet function analyser (PFA-100®) monitoring ("group ASA no PFA") and those in whom the aspirin dosage was adjusted according to PFA-100® results ("group ASA and PFA")." | 3.77 | Is testing for aspirin response worthwhile in high-risk pregnancy? ( Rey, E; Rivard, GE, 2011) |
| "To investigate the effect of a combination of carnosine and aspirin eye drops on the progression of diabetic cataract formation induced by streptozotocin (STZ)." | 3.75 | Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats. ( Harding, JJ; Li, MY; Shi, Q; Yan, H, 2009) |
| "635 Non ST Elevation Acute Coronary Syndrome (NSTE ACS) patients were included and received loading doses of 250 mg aspirin and 600 mg clopidogrel." | 3.75 | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. ( Alessi, MC; Bali, L; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2009) |
| " The quality of control of diabetes, hypertension or hyperlipidemia and the use of aspirin were assessed in 2914 patients at baseline and after 3,7 years." | 3.75 | ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. ( Benke, I; Hanefeld, M; Köhler, C; Ott, P; Stelzer, J, 2009) |
| "05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium." | 3.74 | Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007) |
| " Independent predictors of coronary artery disease were: typical chest pain, aspirin use, diabetes, and age >64 years." | 3.73 | [A new risk score for patients with a normal or non-diagnostic ECG admitted to a chest pain unit]. ( Andueza, J; Bueno, H; de Miguel, J; Estévez, A; Martínez-Sellés, M; Ortiz, J, 2005) |
| "Aspirin for the primary prevention of coronary heart disease (has a more favorable risk/benefit profile among adults with high coronary heart disease risk than among low-risk adults, but there is little information on the current patterns of aspirin use for primary prevention." | 3.73 | Aspirin use for the primary prevention of coronary heart disease in older adults. ( Bauer, DC; Butler, J; Cornuz, J; Ding, J; Harris, TB; Hulley, SB; Newman, AB; Rodondi, N; Satterfield, S; Vittinghoff, E, 2005) |
| ", age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with beta-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin." | 3.70 | Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival. ( Gibbs, NM; Mahon, BD; Newman, MA; Sheminant, MR; Weightman, WM; Whitford, EG, 1999) |
| "To assess the relationship of aspirin use and ischemic cranial nerve palsies among patients with diabetes mellitus and hypertension." | 3.70 | Aspirin use and the prevention of acute ischemic cranial nerve palsy. ( Cipollo, CL; Johnson, LN; Krohel, GB; Madsen, RW; Stetson, SW, 2000) |
| "The results of a case-control study of 300 cataract patients and 609 controls indicate that long-term use of aspirin-like analgesics halves the risk of cataract." | 3.67 | Do aspirin-like analgesics protect against cataract? A case-control study. ( Harding, JJ; van Heyningen, R, 1986) |
| "Retrospective studies on cataract development in patients with rheumatoid arthritis or osteoarthritis revealed a retardant effect of aspirin on diabetic and non-diabetic cataracts." | 3.66 | Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. ( Brescia, M; Cotlier, E; Niven, T; Sharma, YR, 1983) |
| "The prevalence of cataracts is significantly lower in patients with rheumatoid arthritis receiving aspirin (mean of 2,700 mgs daily for an average of 10." | 3.66 | Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes. ( Cotlier, E, 1981) |
| "Patients manifesting intrinsic idiopathic rhinitis and/or asthma in association with diabetes or aspirin intolerance were studied." | 3.65 | Intrinsic asthma associated with diabetes mellitus; abnormal vascular response and glucose tolerance tests. ( Cohen, GN; Fisherman, EW, 1975) |
| "CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0." | 2.80 | The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. ( Gregersen, S; Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S, 2015) |
| "Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy." | 2.74 | Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009) |
| "Observational data from the Early Treatment Diabetic Retinopathy Study." | 2.68 | Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. ( Chantry, K; Chew, EY; Ferris, FL; Hoogwerf, BJ; Klein, ML; Miller, D; Murphy, RP; Remaley, NA, 1996) |
| "The aspirin effect was the same across all risk-factor groups." | 2.66 | Controlled trial of aspirin in cerebral ischemia: an addendum. ( Fields, WS; Gary, HE; Lemak, NA, 1986) |
| "Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation." | 2.47 | TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus. ( Davì, G; Mucci, L; Santilli, F, 2011) |
| "Paralleling the rise in obesity, the cardiometabolic syndrome is a rapidly growing health problem in the United States." | 2.45 | Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. ( Gardner, DW; Gardner, M; Lastra, G; Manrique, C; Palmer, J; Sowers, JR, 2009) |
| "Coronary artery disease is highly prevalent and is the major cause of morbidity and mortality in diabetic patients." | 2.45 | Prevention and management of coronary artery disease in patients with diabetes mellitus. ( Majid, A, 2009) |
| "Diabetes mellitus is a well-recognized risk-factor for coronary artery disease." | 2.43 | [Coronary heart disease in patients with diabetes mellitus]. ( Nakayama, M; Ogawa, H, 2006) |
| "In the United States, pancreatic cancer is the 4(th) leading cause of cancer death, and in Europe it is the 6th." | 2.42 | Epidemiology of pancreatic cancer. ( Michaud, DS, 2004) |
| "Aspirin has a modest effect on reducing stroke." | 2.41 | [Antithrombotic therapy for stroke prevention in patients with atrial fibrillation]. ( Kitabatake, A; Kohya, T; Tomita, F, 2000) |
| "Myocardial infarction is the leading cause of death among persons with diabetes." | 2.41 | Managing myocardial infarction in the diabetic patient. ( Paty, BW, 2000) |
| "Aspirin treatment again has similar benefits to those in non-diabetic subjects, and should be administered at presentation." | 2.40 | Managing the diabetic patient with acute myocardial infarction. ( Yudkin, JS, 1998) |
| "We described the cardioembolic (Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack [CHADS2]/Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, Vascular disease, Age 65-75, Sex category i." | 1.40 | Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. ( Crijns, HJ; Iorio, A; Lip, GY; Marcucci, M; Nieuwlaat, R; Pisters, R, 2014) |
| "Ischemic stroke is a fairly common complication after an AMI in patients with diabetes mellitus, but the risk of stroke has decreased during recent years." | 1.40 | Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus. ( Bergström, L; Björklund, F; Jakobsson, S; Jernberg, T; Mooe, T; Söderström, L, 2014) |
| "Multiple randomized clinical trials have demonstrated that drug eluting stents can significantly reduce the rates of restenosis and subsequent adverse events across lesion and patient." | 1.35 | Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years. ( Chen, JL; Gao, RL; Hu, J; Qiao, SB; Qin, XW; Shen, WF; Xu, B; Yang, YJ; Zhang, JS; Zhang, Q; Zhang, RY, 2008) |
| "Aspirin was the most frequently prescribed adjoining non-anti-hypertensive drugs (39." | 1.33 | Pattern of drug utilization among hypertensives in a Nigerian teaching hospital. ( Balogun, OB; Yusuff, KB, 2005) |
| "Overweight and obesity are well-established risk factors for cardiovascular disease and decline in kidney function in individuals with existing chronic kidney disease (CKD)." | 1.33 | Association between body mass index and CKD in apparently healthy men. ( Buring, JE; Gaziano, JM; Gelber, RP; Kausz, AT; Kurth, T; Levey, AS; Manson, JE, 2005) |
| "Diabetes mellitus is a major public health problem in the United States." | 1.33 | Increased cardiovascular risk associated with diabetes in Dallas County. ( Das, SR; de Lemos, JA; Dobbins, RL; McGuire, DK; Stanek, HG; Vaeth, PA, 2006) |
| "People with diabetes mellitus have higher risk of cardiovascular morbidity and mortality from thrombo-vascular complications than non-diabetics and it is recommended that they should use acetylsalicylic acid (ASA) as anitiplatelet agent regularly." | 1.33 | Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus. ( Drzewoski, J; Liniarski, M; Olszewski, A; Sawer-Szewczyk, J; Stepień, A, 2005) |
| "Diabetes Mellitus is a chronic disease frequently associated to ischemic heart disease and both disease require continuing medical care, aggressive treatment of other risk factors, educational programs for self management of disease to prevent acute complication." | 1.32 | [Recommendations for cardiovascular rehabilitation in diabetes mellitus]. ( Biorci, ML; Camerini, A; Chieffo, C; Comaschi, M; Faglia, E; Fattirolli, F; Gattone, M; Giorda, C; Griffo, R; Mannucci, E, 2003) |
| "Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4." | 1.31 | Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. ( Fagot-Campagna, A; Narayan, KM; Rolka, DB, 2001) |
| "Unstable angina was defined as transient S-T segment changes without significant increases in CK and CK-MB." | 1.31 | Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. ( de Andres, R; Farré, J; García-Méndez, A; Gómez, J; López-Farré, A; Mateos-Cáreres, PJ; Rico, L; Romero, J; Sánchez de Miguel, L, 2002) |
| "Advanced age, previous stroke or transient ischemic attack (TIA), hypertension and diabetes were all found to be risk factors for stroke in patients with atrial fibrillation." | 1.29 | [Atrial fibrillation and apoplexy--risks and prevention]. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1996) |
| "The value of treatment of hyperlipidemia in reducing the incidence of a first stroke remains to be demonstrated." | 1.28 | Ischemic stroke. How to keep the first one from happening. ( Bundlie, SR, 1991) |
| "The overall restenosis rate was 40%." | 1.28 | Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group. ( Bass, T; Cowley, M; Goldberg, SH; Henderson, MA; Hirshfeld, JW; Macdonald, RG; Margolis, JR; Taussig, A; Vetrovec, G; Whitworth, H, 1990) |
| " In the uncommon occurrence of asthma and diabetes in the same patient, insulin dosage should be considered as a factor in all such asthmatics who do not respond well to conventional therapy." | 1.26 | Diabetes mellitus and insulin in an aspirin sensitive asthmatic. ( Caplin, I, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (10.18) | 18.7374 |
| 1990's | 40 (14.55) | 18.2507 |
| 2000's | 117 (42.55) | 29.6817 |
| 2010's | 80 (29.09) | 24.3611 |
| 2020's | 10 (3.64) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, H | 1 |
| Gu, Q | 1 |
| Niu, H | 1 |
| Li, X | 1 |
| Wang, R | 1 |
| Schrör, K | 1 |
| Kristensen, SD | 2 |
| Storey, RF | 2 |
| Verheugt, FWA | 1 |
| Al-Sofiani, ME | 2 |
| Derenbecker, R | 1 |
| Quartuccio, M | 1 |
| Kalyani, RR | 3 |
| Gelbenegger, G | 1 |
| Postula, M | 1 |
| Pecen, L | 1 |
| Halvorsen, S | 1 |
| Lesiak, M | 1 |
| Schoergenhofer, C | 1 |
| Jilma, B | 2 |
| Hengstenberg, C | 1 |
| Siller-Matula, JM | 1 |
| De Caterina, R | 1 |
| Aimo, A | 1 |
| Ridker, PM | 1 |
| Patel, NJ | 1 |
| Baliga, RR | 1 |
| Mitsuboshi, S | 1 |
| Yamada, H | 1 |
| Yamazaki, S | 1 |
| Kobayashi, M | 1 |
| Ueno, K | 1 |
| Nagai, K | 1 |
| Calderone, D | 1 |
| Capodanno, D | 1 |
| Angiolillo, DJ | 3 |
| Batais, MA | 1 |
| Almutairi, KM | 1 |
| Almigbal, TH | 1 |
| Alodhayani, A | 1 |
| Alonazi, WB | 1 |
| Vinluan, JM | 1 |
| Asnar, JB | 1 |
| Salem, RE | 1 |
| Aljubab, RA | 1 |
| Koi, M | 1 |
| Okita, Y | 1 |
| Takeda, K | 1 |
| Koeppe, ES | 1 |
| Stoffel, EM | 1 |
| Galanko, JA | 1 |
| McCoy, AN | 1 |
| Keku, T | 1 |
| Carethers, JM | 1 |
| Wang, HY | 1 |
| Cai, ZX | 1 |
| Yin, D | 1 |
| Yang, YJ | 2 |
| Song, WH | 1 |
| Dou, KF | 1 |
| Wei, S | 1 |
| Yuan, X | 1 |
| Fan, F | 1 |
| Guo, XB | 1 |
| Guan, S | 1 |
| Liu, EY | 1 |
| Yeh, HC | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Joseph, JJ | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Gillani, SW | 1 |
| Sulaiman, SAS | 1 |
| Abdul, MIM | 1 |
| Baig, MR | 1 |
| von Schuckmann, LA | 1 |
| Smith, D | 1 |
| Hughes, MCB | 1 |
| Malt, M | 1 |
| van der Pols, JC | 1 |
| Khosrotehrani, K | 1 |
| Smithers, BM | 1 |
| Green, AC | 1 |
| Leggio, M | 1 |
| Bendini, MG | 1 |
| Caldarone, E | 1 |
| Lombardi, M | 1 |
| Severi, P | 1 |
| D'Emidio, S | 1 |
| Stavri, DC | 1 |
| Armeni, M | 1 |
| Bravi, V | 1 |
| Mazza, A | 1 |
| Zuo, HJ | 1 |
| Wang, WH | 1 |
| Deng, LQ | 1 |
| Su, JL | 1 |
| Majithia, A | 1 |
| Bhatt, DL | 3 |
| Bowman, L | 2 |
| Mafham, M | 2 |
| Wallendszus, K | 2 |
| Stevens, W | 2 |
| Buck, G | 2 |
| Barton, J | 2 |
| Murphy, K | 2 |
| Aung, T | 2 |
| Haynes, R | 2 |
| Cox, J | 2 |
| Murawska, A | 2 |
| Young, A | 2 |
| Lay, M | 2 |
| Chen, F | 2 |
| Sammons, E | 2 |
| Waters, E | 2 |
| Adler, A | 2 |
| Bodansky, J | 2 |
| Farmer, A | 2 |
| McPherson, R | 2 |
| Neil, A | 2 |
| Simpson, D | 2 |
| Peto, R | 2 |
| Baigent, C | 3 |
| Collins, R | 2 |
| Parish, S | 2 |
| Armitage, J | 2 |
| Berkelmans, GFN | 1 |
| Gudbjörnsdottir, S | 1 |
| Visseren, FLJ | 1 |
| Wild, SH | 1 |
| Franzen, S | 1 |
| Chalmers, J | 1 |
| Davis, BR | 1 |
| Poulter, NR | 1 |
| Spijkerman, AM | 1 |
| Woodward, M | 1 |
| Pressel, SL | 1 |
| Gupta, AK | 1 |
| van der Schouw, YT | 1 |
| Svensson, AM | 1 |
| van der Graaf, Y | 1 |
| Read, SH | 1 |
| Eliasson, B | 1 |
| Dorresteijn, JAN | 1 |
| Zheng, SL | 1 |
| Roddick, AJ | 1 |
| Patrono, C | 1 |
| Kautzky-Willer, A | 1 |
| Stich, K | 1 |
| Hintersteiner, J | 1 |
| Kautzky, A | 1 |
| Kamyar, MR | 1 |
| Saukel, J | 1 |
| Johnson, J | 1 |
| Lemmens-Gruber, R | 1 |
| Diener, HC | 2 |
| Saifan, C | 1 |
| El-Charabaty, E | 1 |
| El-Sayegh, S | 2 |
| Okada, S | 3 |
| Morimoto, T | 4 |
| Ogawa, H | 6 |
| Sakuma, M | 3 |
| Soejima, H | 4 |
| Nakayama, M | 3 |
| Sugiyama, S | 1 |
| Jinnouchi, H | 2 |
| Waki, M | 2 |
| Doi, N | 2 |
| Horii, M | 1 |
| Kawata, H | 1 |
| Somekawa, S | 1 |
| Soeda, T | 1 |
| Uemura, S | 1 |
| Saito, Y | 4 |
| Lee, SW | 2 |
| Lee, JY | 2 |
| Ahn, JM | 1 |
| Park, DW | 2 |
| Han, S | 1 |
| Park, YK | 1 |
| Lee, WS | 1 |
| Jang, JY | 1 |
| Kwon, CH | 1 |
| Park, GM | 1 |
| Cho, YR | 1 |
| Kim, WJ | 2 |
| Kang, SJ | 1 |
| Kim, YH | 2 |
| Lee, CW | 2 |
| Kim, JJ | 1 |
| Park, SW | 2 |
| Park, SJ | 2 |
| Kawamura, N | 1 |
| Ito, Y | 1 |
| Sasaki, M | 1 |
| Iida, A | 1 |
| Mizuno, M | 1 |
| Ogasawara, N | 1 |
| Funaki, Y | 1 |
| Kasugai, K | 1 |
| Simpson, SH | 1 |
| Abdelmoneim, AS | 1 |
| Omran, D | 1 |
| Featherstone, TR | 1 |
| Jakobsson, S | 1 |
| Bergström, L | 1 |
| Björklund, F | 1 |
| Jernberg, T | 1 |
| Söderström, L | 1 |
| Mooe, T | 1 |
| Hafez, G | 1 |
| Gonulalan, U | 1 |
| Kosan, M | 1 |
| Arioglu, E | 1 |
| Ozturk, B | 1 |
| Cetinkaya, M | 1 |
| Gur, S | 1 |
| Tisminetzky, M | 1 |
| Joffe, S | 1 |
| McManus, DD | 1 |
| Darling, C | 1 |
| Gore, JM | 1 |
| Yarzebski, J | 1 |
| Lessard, D | 1 |
| Goldberg, RJ | 1 |
| Marcucci, M | 1 |
| Lip, GY | 1 |
| Nieuwlaat, R | 1 |
| Pisters, R | 1 |
| Crijns, HJ | 1 |
| Iorio, A | 1 |
| Diaz, VA | 1 |
| Dickerson, LM | 1 |
| Smith, LL | 1 |
| Seawright, K | 1 |
| Wessell, A | 1 |
| Gavin, JK | 1 |
| Chirina, S | 1 |
| Knoll, M | 1 |
| Player, MS | 1 |
| McCutcheon, A | 1 |
| Dervisevik, M | 1 |
| Dinevska-Kovkarovska, S | 1 |
| Dimitrovska, M | 1 |
| Cipanovska, N | 1 |
| Miova, B | 1 |
| Une, D | 1 |
| Al-Atassi, T | 1 |
| Kulik, A | 1 |
| Voisine, P | 1 |
| Le May, M | 1 |
| Ruel, M | 1 |
| Silber, T | 1 |
| Ziemann, U | 1 |
| Ernemann, U | 1 |
| Bischof, F | 1 |
| Lin, CC | 1 |
| Lai, MS | 1 |
| Shau, WY | 1 |
| DeFilippis, AP | 1 |
| Young, R | 1 |
| Carrubba, CJ | 1 |
| McEvoy, JW | 1 |
| Budoff, MJ | 1 |
| Blumenthal, RS | 1 |
| Kronmal, RA | 1 |
| McClelland, RL | 1 |
| Nasir, K | 1 |
| Blaha, MJ | 1 |
| Kuliczkowski, W | 2 |
| Gasior, M | 2 |
| Pres, D | 2 |
| Kaczmarski, J | 2 |
| Laszowska, A | 1 |
| Szewczyk, M | 1 |
| Hawranek, M | 1 |
| Tajstra, M | 1 |
| Zeglen, S | 1 |
| Polonski, L | 2 |
| Serebruany, VL | 2 |
| Parhofer, KG | 1 |
| Gold, R | 2 |
| Nelson, C | 1 |
| Cowburn, S | 1 |
| Bunce, A | 1 |
| Hollombe, C | 2 |
| Davis, J | 1 |
| Muench, J | 1 |
| Hill, C | 1 |
| Mital, M | 1 |
| Puro, J | 1 |
| Perrin, N | 1 |
| Nichols, G | 1 |
| Turner, A | 1 |
| Mercer, M | 1 |
| Jaworski, V | 1 |
| Howard, C | 1 |
| Abiles, E | 1 |
| Shah, A | 1 |
| Dudl, J | 1 |
| Chan, W | 1 |
| DeVoe, J | 1 |
| Neergaard-Petersen, S | 1 |
| Hvas, AM | 1 |
| Grove, EL | 1 |
| Larsen, SB | 1 |
| Gregersen, S | 1 |
| Zanders, MM | 1 |
| van Herk-Sukel, MP | 1 |
| Vissers, PA | 1 |
| Herings, RM | 1 |
| Haak, HR | 1 |
| van de Poll-Franse, LV | 1 |
| Suwita, BM | 1 |
| Laksmi, PW | 1 |
| Wijaya, IP | 1 |
| Bell, DS | 1 |
| Qamar, A | 1 |
| Bunce, AE | 1 |
| Cohen, DJ | 1 |
| Nelson, CA | 1 |
| Proctor, EK | 1 |
| Pope, JA | 1 |
| DeVoe, JE | 1 |
| Nardin, M | 1 |
| Verdoia, M | 1 |
| Sartori, C | 1 |
| Pergolini, P | 1 |
| Rolla, R | 1 |
| Barbieri, L | 1 |
| Schaffer, A | 1 |
| Bellomo, G | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Kokoska, LA | 1 |
| Wilhelm, SM | 1 |
| Garwood, CL | 1 |
| Berlie, HD | 1 |
| Pan, Y | 1 |
| Jing, J | 1 |
| Li, H | 1 |
| Wang, Y | 2 |
| He, Y | 1 |
| Masuda, I | 1 |
| Maeng, M | 1 |
| Jensen, LO | 1 |
| Kaltoft, A | 1 |
| Hansen, HH | 1 |
| Bøttcher, M | 1 |
| Lassen, JF | 1 |
| Thayssen, P | 1 |
| Krusell, LR | 1 |
| Rasmussen, K | 1 |
| Pedersen, L | 1 |
| Sørensen, HT | 1 |
| Johnsen, SP | 1 |
| Thuesen, L | 1 |
| Zhang, Q | 1 |
| Xu, B | 1 |
| Qiao, SB | 1 |
| Zhang, RY | 1 |
| Zhang, JS | 1 |
| Hu, J | 1 |
| Qin, XW | 1 |
| Chen, JL | 1 |
| Shen, WF | 1 |
| Gao, RL | 1 |
| Farkouh, ME | 1 |
| Fuster, V | 1 |
| Ott, P | 1 |
| Benke, I | 1 |
| Stelzer, J | 1 |
| Köhler, C | 1 |
| Hanefeld, M | 1 |
| Majid, A | 1 |
| Azuz, N | 1 |
| Thomas, K | 1 |
| Yaffe, Y | 1 |
| Katz, M | 1 |
| Weingarten, M | 1 |
| Matalon, A | 1 |
| Bousser, MG | 1 |
| Amarenco, P | 1 |
| Chamorro, A | 1 |
| Fisher, M | 2 |
| Ford, I | 1 |
| Fox, K | 1 |
| Hennerici, M | 1 |
| Mattle, HP | 1 |
| Rothwell, PM | 1 |
| Motovska, Z | 1 |
| Widimsky, P | 1 |
| Gardner, M | 1 |
| Palmer, J | 1 |
| Manrique, C | 1 |
| Lastra, G | 1 |
| Gardner, DW | 1 |
| Sowers, JR | 2 |
| Torres Baile, JL | 1 |
| Ortega Sánchez, G | 1 |
| Welin, L | 1 |
| Wilhelmsen, L | 1 |
| Björnberg, A | 1 |
| Odén, A | 1 |
| Kojima, S | 1 |
| Klomp, CM | 1 |
| ten Cate, H | 1 |
| Stehouwer, CD | 1 |
| Schaper, NC | 1 |
| Benhamou, Y | 1 |
| Lévesque, H | 1 |
| Shi, Q | 1 |
| Yan, H | 1 |
| Li, MY | 1 |
| Harding, JJ | 4 |
| Chun, KJ | 1 |
| Kim, HS | 1 |
| Yun, SC | 1 |
| Hong, MK | 1 |
| Rhee, KS | 1 |
| Chae, JK | 1 |
| Ko, JK | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Choi, SW | 1 |
| Jeong, JO | 1 |
| Seong, IW | 1 |
| Jon, S | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Kim, JH | 2 |
| LaMarr, B | 1 |
| Valdez, C | 1 |
| Driscoll, K | 1 |
| Ryan, M | 1 |
| Fumeaux, D | 1 |
| Becerra, ME | 1 |
| Philippe, J | 1 |
| Louis-Simonet, M | 1 |
| Gross, H | 1 |
| Morel, O | 1 |
| Kessler, L | 1 |
| Ohlmann, P | 1 |
| Bareiss, P | 1 |
| Pignone, M | 3 |
| Alberts, MJ | 2 |
| Colwell, JA | 7 |
| Cushman, M | 2 |
| Inzucchi, SE | 2 |
| Mukherjee, D | 2 |
| Rosenson, RS | 2 |
| Williams, CD | 3 |
| Wilson, PW | 2 |
| Kirkman, MS | 2 |
| Geara, AS | 1 |
| Azzi, N | 1 |
| Bassil, C | 1 |
| Morgan, GP | 1 |
| Martin-Carrillo, P | 1 |
| Añino, A | 1 |
| Pinar, O | 1 |
| Fernandez, I | 1 |
| Saenz, A | 1 |
| Ausejo, M | 1 |
| Parker, R | 1 |
| Gul, R | 1 |
| Bucknall, V | 1 |
| Bowley, D | 1 |
| Karandikar, S | 1 |
| Santilli, F | 1 |
| Mucci, L | 1 |
| Davì, G | 1 |
| Drouet, L | 1 |
| Bal dit Sollier, C | 1 |
| Henry, P | 1 |
| Gilpin, VL | 1 |
| Galloway, CF | 1 |
| Stevenson, JC | 1 |
| Stavrakis, S | 1 |
| Stoner, JA | 1 |
| Azar, M | 1 |
| Wayangankar, S | 1 |
| Thadani, U | 1 |
| Mangiacapra, F | 1 |
| Peace, AJ | 1 |
| Wijns, W | 1 |
| Barbato, E | 1 |
| Marioni, RE | 1 |
| Deary, IJ | 1 |
| Murray, GD | 1 |
| Lowe, GD | 1 |
| Strachan, MW | 1 |
| Luciano, M | 1 |
| Houlihan, LM | 1 |
| Gow, AJ | 1 |
| Harris, SE | 1 |
| Rumley, A | 1 |
| Stewart, MC | 1 |
| Fowkes, FG | 1 |
| Price, JF | 1 |
| Rey, E | 1 |
| Rivard, GE | 1 |
| Butalia, S | 1 |
| Leung, AA | 1 |
| Ghali, WA | 1 |
| Rabi, DM | 1 |
| Greif, M | 1 |
| Shinohara, Y | 2 |
| Bhatt, LK | 1 |
| Addepalli, V | 1 |
| Ferreiro, JL | 1 |
| Cequier, AR | 1 |
| Chopra, V | 1 |
| Hayward, RA | 1 |
| Schnell, O | 2 |
| Erbach, M | 1 |
| Hummel, M | 1 |
| Park, JY | 1 |
| Rha, SW | 1 |
| Poddar, KL | 1 |
| Ramasamy, S | 1 |
| Chen, KY | 1 |
| Li, YJ | 1 |
| Choi, BG | 1 |
| Ryu, SK | 1 |
| Choi, JW | 1 |
| Park, SH | 1 |
| Park, S | 1 |
| Elnagar, A | 1 |
| Im, SI | 1 |
| Kim, SW | 1 |
| Na, JO | 1 |
| Choi, CU | 1 |
| Lim, HE | 1 |
| Kim, JW | 2 |
| Kim, EJ | 1 |
| Han, SW | 1 |
| Park, CG | 2 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Van Hattum, ES | 1 |
| Tangelder, MJ | 1 |
| Lawson, JA | 1 |
| Moll, FL | 1 |
| Algra, A | 1 |
| Ajjan, RA | 1 |
| Hess, CN | 1 |
| Broderick, S | 1 |
| Piccini, JP | 1 |
| Alexander, KP | 1 |
| Newby, LK | 1 |
| Shaw, LK | 1 |
| Mahaffey, KW | 1 |
| Alexander, JH | 1 |
| Peterson, ED | 1 |
| Granger, CB | 1 |
| Lopes, RD | 1 |
| Levy, IG | 1 |
| Pim, CP | 1 |
| Suh, S | 1 |
| Seo, PJ | 1 |
| Park, H | 1 |
| Shin, CM | 1 |
| Jo, HJ | 1 |
| Kim, HY | 1 |
| Lee, SH | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Jeong, SH | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Song, IS | 1 |
| Jung, HC | 1 |
| Marso, SP | 1 |
| Hirsch, AT | 1 |
| Ringleb, PA | 1 |
| Hacke, W | 1 |
| Topol, EJ | 1 |
| Mehta, JL | 1 |
| Grenier, O | 1 |
| Cambou, JP | 1 |
| Ferrières, J | 1 |
| Thomas, D | 1 |
| Amelineau, E | 1 |
| Cantet, C | 1 |
| Danchin, N | 1 |
| Faragon, JJ | 1 |
| Waite, NM | 1 |
| Hobson, EH | 1 |
| Seoldo, N | 1 |
| VanAmburgh, JA | 1 |
| Migden, H | 1 |
| Mateos-Cáreres, PJ | 1 |
| García-Méndez, A | 1 |
| Farré, J | 1 |
| Sánchez de Miguel, L | 1 |
| Gómez, J | 1 |
| de Andres, R | 1 |
| Rico, L | 1 |
| Romero, J | 1 |
| López-Farré, A | 1 |
| Eichenberger, A | 1 |
| Pontiggia, L | 1 |
| Beer, JH | 1 |
| Brown, AF | 1 |
| Mangione, CM | 1 |
| Saliba, D | 1 |
| Sarkisian, CA | 1 |
| Ali Raza, J | 1 |
| Movahed, A | 1 |
| Mohri, M | 1 |
| Rollins, G | 1 |
| Schröder, H | 1 |
| Oganov, RG | 1 |
| Lepakhin, VK | 1 |
| Fitilev, SB | 1 |
| Levin, AM | 1 |
| Titarova, YY | 1 |
| Sytchev, EN | 1 |
| Demir, I | 1 |
| Yilmaz, H | 1 |
| Basarici, I | 1 |
| Sancaktar, O | 1 |
| Deger, N | 1 |
| Morimoto, S | 1 |
| Nemoto, M | 1 |
| Han, A | 1 |
| Katoh, S | 1 |
| Kurata, H | 1 |
| Utsunomiya, K | 1 |
| Tajima, N | 1 |
| Nakajima, M | 1 |
| Kimura, K | 1 |
| Minematsu, K | 1 |
| Saito, K | 1 |
| Takada, T | 1 |
| Tanaka, M | 1 |
| Gohlke, H | 1 |
| Schirmer, A | 1 |
| Theobald, KH | 1 |
| Camerini, A | 1 |
| Chieffo, C | 1 |
| Griffo, R | 1 |
| Comaschi, M | 1 |
| Gattone, M | 1 |
| Mannucci, E | 1 |
| Faglia, E | 1 |
| Giorda, C | 1 |
| Biorci, ML | 1 |
| Fattirolli, F | 1 |
| Negri, M | 1 |
| Martignoni, A | 1 |
| Baccheschi, J | 1 |
| Santilli, G | 1 |
| Marchesi, E | 1 |
| Michaud, DS | 1 |
| Locker, C | 1 |
| Mohr, R | 1 |
| Lev-Ran, O | 1 |
| Uretzky, G | 1 |
| Frimerman, A | 1 |
| Shaham, Y | 1 |
| Shapira, I | 1 |
| de Abajo, FJ | 1 |
| García Rodríguez, LA | 1 |
| Sicras Mainar, A | 1 |
| Ruiz Riera, R | 1 |
| Frías Garrido, X | 1 |
| Navarro Artieda, R | 1 |
| Barquero Romero, J | 1 |
| Masero Carretero, A | 1 |
| Pérez Miranda, M | 1 |
| González-Clemente, JM | 1 |
| Barahona, MJ | 1 |
| Giménez-Pérez, G | 1 |
| Mauricio, D | 1 |
| Diogène, E | 1 |
| Agustí, A | 1 |
| Roberts, SS | 1 |
| Soares, AS | 1 |
| Artes, PH | 1 |
| Andreou, P | 1 |
| Leblanc, RP | 1 |
| Chauhan, BC | 1 |
| Nicolela, MT | 1 |
| Fulcher, GR | 1 |
| Amarena, JV | 1 |
| Conner, GW | 1 |
| Gilbert, RE | 1 |
| Hankey, GJ | 2 |
| de Lange, DW | 1 |
| Fiets, WE | 1 |
| Banga, JD | 1 |
| Nobles-James, C | 1 |
| James, EA | 1 |
| Yusuff, KB | 1 |
| Balogun, OB | 1 |
| Standl, E | 1 |
| Popma, JJ | 1 |
| Leon, MB | 1 |
| Moses, JW | 1 |
| Holmes, DR | 1 |
| Cox, N | 1 |
| Fitzpatrick, M | 1 |
| Douglas, J | 1 |
| Lambert, C | 1 |
| Mooney, M | 1 |
| Yakubov, S | 1 |
| Kuntz, RE | 1 |
| Evangelista, V | 1 |
| Totani, L | 1 |
| Rotondo, S | 1 |
| Lorenzet, R | 1 |
| Tognoni, G | 1 |
| De Berardis, G | 1 |
| Nicolucci, A | 1 |
| Edmisson, KW | 1 |
| Gurevich, MA | 1 |
| Martínez-Sellés, M | 1 |
| Ortiz, J | 1 |
| Estévez, A | 1 |
| Andueza, J | 1 |
| de Miguel, J | 1 |
| Bueno, H | 1 |
| McQueen, MJ | 1 |
| Lonn, E | 1 |
| Gerstein, HC | 1 |
| Bosch, J | 1 |
| Yusuf, S | 1 |
| Katayama, T | 1 |
| Nakashima, H | 1 |
| Takagi, C | 1 |
| Honda, Y | 1 |
| Suzuki, S | 1 |
| Iwasaki, Y | 1 |
| Yano, K | 1 |
| Gelber, RP | 1 |
| Kurth, T | 1 |
| Kausz, AT | 1 |
| Manson, JE | 2 |
| Buring, JE | 1 |
| Levey, AS | 1 |
| Gaziano, JM | 1 |
| Rodondi, N | 1 |
| Vittinghoff, E | 1 |
| Cornuz, J | 1 |
| Butler, J | 1 |
| Ding, J | 1 |
| Satterfield, S | 1 |
| Newman, AB | 1 |
| Harris, TB | 1 |
| Hulley, SB | 1 |
| Bauer, DC | 1 |
| Cimminiello, C | 2 |
| Ajani, UA | 1 |
| Ford, ES | 1 |
| Greenland, KJ | 1 |
| Giles, WH | 1 |
| Mokdad, AH | 1 |
| Fernandez-Ortiz, A | 1 |
| Bernardo, E | 1 |
| Ramírez, C | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Hernández, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Costa, MA | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Das, SR | 1 |
| Vaeth, PA | 1 |
| Stanek, HG | 1 |
| de Lemos, JA | 1 |
| Dobbins, RL | 1 |
| McGuire, DK | 1 |
| Drzewoski, J | 1 |
| Sawer-Szewczyk, J | 1 |
| Stepień, A | 1 |
| Olszewski, A | 1 |
| Liniarski, M | 1 |
| Soares, PR | 1 |
| Hueb, WA | 1 |
| Lemos, PA | 1 |
| Lopes, N | 1 |
| Martinez, EE | 1 |
| Cesar, LA | 1 |
| Oliveira, SA | 1 |
| Ramires, JA | 1 |
| Késmárky, G | 1 |
| Fehér, G | 1 |
| Koltai, K | 1 |
| Horváth, B | 1 |
| Tóth, K | 1 |
| Sibbing, D | 1 |
| von Beckerath, O | 1 |
| Schömig, A | 1 |
| Kastrati, A | 1 |
| von Beckerath, N | 1 |
| Ganea, E | 1 |
| Legrand, DA | 3 |
| Scheen, AJ | 3 |
| Fuchs, I | 1 |
| Frossard, M | 1 |
| Spiel, A | 1 |
| Riedmüller, E | 1 |
| Laggner, AN | 1 |
| Khalifeh, MR | 1 |
| Redett, RJ | 1 |
| Lewis, JD | 1 |
| Schinnar, R | 1 |
| Bilker, WB | 1 |
| Wang, X | 1 |
| Strom, BL | 1 |
| Kotake, H | 1 |
| Oikawa, S | 1 |
| Ambrosi, P | 1 |
| Villani, P | 1 |
| Bouvenot, G | 1 |
| Grinius, V | 1 |
| Navickas, R | 1 |
| Unikas, R | 1 |
| Varma, SD | 1 |
| Hegde, KR | 1 |
| Lima Filho, Mde O | 1 |
| Figueiredo, GL | 1 |
| Haddad, JL | 1 |
| Schmidt, A | 1 |
| Lima, NK | 1 |
| Pischon, T | 1 |
| Möhlig, M | 1 |
| Hoffmann, K | 1 |
| Spranger, J | 1 |
| Weikert, C | 1 |
| Willich, SN | 1 |
| Pfeiffer, AF | 1 |
| Boeing, H | 1 |
| Shekelle, P | 1 |
| Vijan, S | 1 |
| Tirnaksiz, E | 1 |
| Pamukcu, B | 1 |
| Oflaz, H | 1 |
| Nisanci, Y | 1 |
| Matsumoto, T | 1 |
| Morrow, DA | 1 |
| Antman, EM | 1 |
| Murphy, SA | 1 |
| Qin, J | 1 |
| Ruda, M | 1 |
| Guneri, S | 1 |
| Jacob, AJ | 1 |
| Budaj, A | 1 |
| Braunwald, E | 1 |
| Ahn, Y | 1 |
| Jeong, MH | 1 |
| Jeong, JW | 1 |
| Kim, KH | 1 |
| Ahn, TH | 1 |
| Kang, WC | 1 |
| Chae, IH | 1 |
| Nam, CW | 1 |
| Hur, SH | 1 |
| Bae, JH | 1 |
| Kim, KY | 1 |
| Oh, SK | 1 |
| Ajjan, R | 1 |
| Grant, PJ | 1 |
| Wienbergen, H | 1 |
| Senges, J | 2 |
| Gitt, AK | 1 |
| Smith, DA | 1 |
| Smith, PJ | 1 |
| Hurlen, M | 1 |
| Abdelnoor, M | 1 |
| Arnesen, H | 1 |
| Masanauskiene, E | 1 |
| Naudziūnas, A | 1 |
| Sirois, C | 1 |
| Poirier, P | 1 |
| Moisan, J | 1 |
| Grégoire, JP | 1 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Morange, PE | 1 |
| Camoin, L | 1 |
| Bali, L | 1 |
| Lambert, M | 1 |
| Juhan-Vague, I | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Ek, I | 1 |
| Thunell, S | 1 |
| Blombäck, M | 1 |
| Cotlier, E | 3 |
| Sharma, YR | 1 |
| Niven, T | 1 |
| Brescia, M | 1 |
| Tindall, H | 1 |
| Paton, RC | 1 |
| Zuzel, M | 1 |
| McNicol, GP | 1 |
| Bronner, LL | 1 |
| Kanter, DS | 1 |
| Gorelick, PB | 1 |
| Chew, EY | 3 |
| Klein, ML | 2 |
| Murphy, RP | 2 |
| Remaley, NA | 3 |
| Ferris, FL | 3 |
| Biller, J | 1 |
| Love, BB | 1 |
| Grotta, J | 1 |
| Blackshear, JL | 1 |
| Kopecky, SL | 1 |
| Litin, SC | 1 |
| Safford, RE | 1 |
| Hammill, SC | 1 |
| Heath, MM | 1 |
| Rixon, KC | 1 |
| Koefoed, BG | 1 |
| Gulløv, AL | 1 |
| Petersen, P | 1 |
| Chantry, K | 1 |
| Hoogwerf, BJ | 1 |
| Miller, D | 1 |
| Milani, M | 1 |
| Ceriello, A | 1 |
| Motz, E | 1 |
| Yudkin, JS | 2 |
| Rockwood, K | 1 |
| Ebly, E | 1 |
| Hachinski, V | 1 |
| Hogan, D | 1 |
| Calvo, F | 1 |
| Barrabés, JA | 1 |
| García-Dorado, D | 1 |
| Laperche, T | 1 |
| Laurian, C | 1 |
| Roudaut, R | 1 |
| Steg, PG | 1 |
| Talwar, S | 1 |
| Maxwell, S | 1 |
| Gascón Ramón, G | 1 |
| Bertomeu i Blanch, F | 1 |
| Baño Aracil, M | 1 |
| Madrigal, JA | 1 |
| MacDonald, TM | 1 |
| Butler, R | 1 |
| Newton, RW | 1 |
| Morris, AD | 1 |
| Barron, HV | 1 |
| Michaels, AD | 1 |
| Maynard, C | 1 |
| Every, NR | 1 |
| Evans, MF | 1 |
| Chiamvimonvat, V | 1 |
| Sternberg, L | 1 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Sheminant, MR | 1 |
| Whitford, EG | 1 |
| Mahon, BD | 1 |
| Newman, MA | 1 |
| Vidt, DG | 1 |
| Pohl, MA | 1 |
| Herlitz, J | 1 |
| Malmberg, K | 1 |
| Lewis, L | 1 |
| Chowdhury, TA | 1 |
| Lasker, SS | 1 |
| Dyer, PH | 1 |
| Futterman, LG | 1 |
| Lemberg, L | 1 |
| Johnson, LN | 1 |
| Stetson, SW | 1 |
| Krohel, GB | 1 |
| Cipollo, CL | 1 |
| Madsen, RW | 1 |
| Steinberg, H | 1 |
| Tomita, F | 1 |
| Kohya, T | 1 |
| Kitabatake, A | 1 |
| Hildebrandt, PR | 1 |
| Snorgaard, O | 1 |
| Melchior, TM | 1 |
| Seibaek, MB | 1 |
| Torp-Pedersen, CT | 1 |
| Poulter, N | 1 |
| Guize, L | 1 |
| Ducimetière, P | 1 |
| Consoli, SM | 1 |
| Kolsky, H | 1 |
| Raynaud, P | 1 |
| Walch, JM | 1 |
| Paul-Dauphin, A | 1 |
| Duprat-Lomon, I | 1 |
| Théroux, P | 1 |
| Alexander, J | 1 |
| Pharand, C | 1 |
| Barr, E | 1 |
| Snapinn, S | 1 |
| Ghannam, AF | 1 |
| Sax, FL | 1 |
| Paty, BW | 1 |
| Rolka, DB | 1 |
| Fagot-Campagna, A | 1 |
| Narayan, KM | 1 |
| Bassand, JP | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Lowry, DR | 1 |
| Lecompte, T | 1 |
| Kennedy, J | 1 |
| Mogensen, CE | 1 |
| Ball, SG | 1 |
| Castaigne, AD | 1 |
| Commerford, PJ | 1 |
| Distiller, L | 1 |
| Fisher, BM | 1 |
| Gonzalez-Jaunatey, J | 1 |
| Nosadini, R | 1 |
| Novials, A | 1 |
| Ostergren, J | 1 |
| Palma-Gámiz, J | 1 |
| Perrone-Filardi, P | 1 |
| Schipperheijn, JJ | 1 |
| Trevisan, R | 1 |
| George, PB | 1 |
| Tobin, KJ | 1 |
| Corpus, RA | 1 |
| Devlin, WH | 1 |
| O'Neill, WW | 1 |
| Weisser, B | 1 |
| Düsing, R | 1 |
| Mengden, T | 1 |
| Abramson, B | 1 |
| Fored, CM | 1 |
| Ejerblad, E | 1 |
| Lindblad, P | 1 |
| Fryzek, JP | 1 |
| Dickman, PW | 1 |
| Signorello, LB | 1 |
| Lipworth, L | 1 |
| Elinder, CG | 1 |
| Blot, WJ | 1 |
| McLaughlin, JK | 1 |
| Zack, MM | 1 |
| Nyrén, O | 1 |
| Prisco, D | 1 |
| Doughty, M | 1 |
| Mehta, R | 1 |
| Bruckman, D | 1 |
| Das, S | 1 |
| Karavite, D | 1 |
| Tsai, T | 1 |
| Eagle, K | 1 |
| Maharaj, R | 1 |
| Brouwer, MA | 1 |
| Verheugt, FW | 1 |
| Fisherman, EW | 3 |
| Rosset, D | 1 |
| Cohen, GN | 3 |
| Abrishami, MA | 1 |
| Thomas, J | 1 |
| Burry, A | 1 |
| Cross, R | 1 |
| Axelsen, R | 1 |
| Vinceneux, P | 1 |
| Lubetski, D | 1 |
| Kahn, MF | 1 |
| Prof Aiuto, G | 1 |
| Langman, MJ | 1 |
| Browder, A | 1 |
| Browder, J | 1 |
| Caplin, I | 1 |
| Williams, GA | 1 |
| Burton, TC | 1 |
| Barton, FB | 1 |
| Terres, W | 1 |
| Hamm, CW | 1 |
| Ruchelka, A | 1 |
| Weilepp, A | 1 |
| Kupper, W | 1 |
| Sivenius, J | 1 |
| Laakso, M | 1 |
| Riekkinen, P | 1 |
| Smets, P | 1 |
| Lowenthal, A | 1 |
| Bundlie, SR | 1 |
| Belcaro, G | 1 |
| De Simone, P | 1 |
| Macdonald, RG | 1 |
| Henderson, MA | 1 |
| Hirshfeld, JW | 1 |
| Goldberg, SH | 1 |
| Bass, T | 1 |
| Vetrovec, G | 1 |
| Cowley, M | 1 |
| Taussig, A | 1 |
| Whitworth, H | 1 |
| Margolis, JR | 1 |
| van Heyningen, R | 1 |
| Lemak, NA | 1 |
| Fields, WS | 1 |
| Gary, HE | 1 |
| Bingham, SF | 1 |
| Hun-Opfer, C | 1 |
| Mata-Segreda, JF | 1 |
| Grzesik, J | 1 |
| Rzymełka, S | 1 |
| Hawtrey, CE | 1 |
| Williams, JJ | 1 |
| Schmidt, JD | 1 |
| Loew, D | 1 |
| Wellmer, HK | 1 |
| Baer, U | 1 |
| Merguet, H | 1 |
| Rumpf, P | 1 |
| Petersen, H | 1 |
| Bromig, G | 1 |
| Persch, WF | 1 |
| Marx, FJ | 1 |
| von Bary, SM | 1 |
| Feldman, JM | 1 |
| Kelley, WN | 1 |
| Lebovitz, HE | 1 |
| Davies, DJ | 1 |
| Kennedy, A | 1 |
| Roberts, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging[NCT05845489] | Phase 4 | 9,930 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883] | 1,120 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | |||
| A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes[NCT00135226] | Phase 4 | 15,480 participants (Actual) | Interventional | 2005-03-31 | Active, not recruiting | ||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II[NCT05702463] | Phase 1 | 30 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes: APPEASED Study Phase 1[NCT05105919] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy[NCT05553717] | 66 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics[NCT02299791] | 4,856 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448] | Phase 4 | 2,539 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156] | 4,118 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | |||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study[NCT01480804] | 48 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Identifying and Overcoming Barriers to Diabetes Management in the Elderly: A Cost-effective Intervention Study[NCT01486290] | 52 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| ABILITY Diabetes Global[NCT04236609] | 3,050 participants (Actual) | Interventional | 2020-06-15 | Active, not recruiting | |||
| [NCT00000151] | Phase 3 | 0 participants | Interventional | 1979-12-31 | Completed | ||
| Do Innovative Strategies Complement Medical Management to Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?[NCT00462436] | Phase 2 | 35 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University[NCT03266328] | 117 participants (Anticipated) | Observational | 2017-09-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 157 |
| Placebo Aspirin | 158 |
"Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of SVE or revascularization (including coronary and non-coronary revascularizations)." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 833 |
| Placebo Aspirin | 936 |
| Omega-3 | 882 |
| Placebo Omega-3 | 887 |
"Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.~A single participant may have had multiple cancers." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 897 |
| Placebo Aspirin | 887 |
| Omega-3 | 894 |
| Placebo Omega-3 | 890 |
Includes fatal and non-fatal events. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 166 |
| Placebo Omega-3 | 135 |
Includes fatal and non-fatal cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 97 |
| Placebo Aspirin | 96 |
| Omega-3 | 103 |
| Placebo Omega-3 | 90 |
Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 332 |
| Placebo Aspirin | 294 |
| Omega-3 | 323 |
| Placebo Omega-3 | 303 |
Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 88 |
| Placebo Aspirin | 86 |
| Omega-3 | 94 |
| Placebo Omega-3 | 80 |
Includes fatal and non-fatal melanomas. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 50 |
| Placebo Aspirin | 59 |
| Omega-3 | 55 |
| Placebo Omega-3 | 54 |
Includes fatal and non-fatal events, excludes atrial fibrillation. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 83 |
| Placebo Omega-3 | 99 |
Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 25 |
| Placebo Aspirin | 30 |
| Omega-3 | 23 |
| Placebo Omega-3 | 32 |
Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 87 |
| Placebo Aspirin | 82 |
Includes fatal and non-fatal cancers. Includes lung and larynx cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 101 |
| Placebo Aspirin | 103 |
| Omega-3 | 104 |
| Placebo Omega-3 | 100 |
Includes fatal and non-fatal cancers of unknown type. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 26 |
| Placebo Aspirin | 31 |
| Omega-3 | 25 |
| Placebo Omega-3 | 32 |
Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 38 |
| Placebo Aspirin | 34 |
| Omega-3 | 35 |
| Placebo Omega-3 | 37 |
'All-cause mortality' includes all recorded deaths. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 748 |
| Placebo Aspirin | 792 |
| Omega-3 | 752 |
| Placebo Omega-3 | 788 |
Fatal 'Cancer' events include any death attributed to cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 309 |
| Placebo Aspirin | 315 |
| Omega-3 | 305 |
| Placebo Omega-3 | 319 |
Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 105 |
| Placebo Aspirin | 122 |
| Omega-3 | 100 |
| Placebo Omega-3 | 127 |
Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 18 |
| Placebo Aspirin | 21 |
| Omega-3 | 17 |
| Placebo Omega-3 | 22 |
Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 126 |
| Placebo Aspirin | 157 |
| Omega-3 | 158 |
| Placebo Omega-3 | 125 |
Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 67 |
| Placebo Aspirin | 70 |
| Omega-3 | 61 |
| Placebo Omega-3 | 76 |
Fatal 'Respiratory' events include any death attributed to respiratory causes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 82 |
| Placebo Aspirin | 69 |
| Omega-3 | 73 |
| Placebo Omega-3 | 78 |
Any death for which the cause is not known. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 3 |
| Placebo Aspirin | 4 |
| Omega-3 | 3 |
| Placebo Omega-3 | 4 |
"The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of any major bleed, defined as:~any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or~sight-threatening eye bleeding; or~any other serious bleeding episode." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 314 |
| Placebo Aspirin | 245 |
"The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any Serious Vascular Event (SVE), defined as:~non-fatal myocardial infarction; or~non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or~vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62])." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 658 |
| Placebo Aspirin | 743 |
| Omega-3 | 689 |
| Placebo Omega-3 | 712 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
Number of patients indicated for ACE/ARB and statin who had an active prescription for both, as a proportion of patients indicated for ACE/ARB and statin. (NCT02299791)
Timeframe: Percent of clinic patients prescribed guideline-concordant cardioprotective medications, as of the 1st day of each month, from up to 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Early Intervention | 1279 |
| Late Implementation | 1318 |
84 reviews available for aspirin and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Diabetic Cardiomyop | 2021 |
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2019 |
Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes: a Review of the Evidence.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Humans; Primary Pre | 2019 |
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA | 2019 |
Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review.
Topics: Aged; Aspirin; Cardiology; Cardiovascular Diseases; Cardiovascular System; Diabetes Complications; H | 2020 |
Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Case-Control Studies; Diabetes Complications; Diabetes Melli | 2020 |
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Complications; Drug Therapy, Co | 2020 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Fibrinolytic Agents; Humans; Primary Preve | 2018 |
Antiplatelet Therapy in Diabetes.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors | 2018 |
Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Female; Hemorrhage; Hum | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationshi | 2014 |
[Aspirin and statins for every diabetic?].
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Ther | 2015 |
Extended Dual Antiplatelet for Diabetic Elderly Patients After Drug-eluting Stent Implantation: an Evidence-based Clinical Review.
Topics: Aged; Aspirin; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Drug-Eluting Ste | 2015 |
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Diabetes C | 2016 |
Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2016 |
Prevention and management of coronary artery disease in patients with diabetes mellitus.
Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2009 |
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Dia | 2009 |
Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
Topics: Aspirin; Blood Coagulation; Blood Glucose; Blood Platelets; Cardiovascular Agents; Cardiovascular Di | 2009 |
Clinical evidence for Japanese population based on prospective studies--linking clinical trials and clinical practice.
Topics: Adrenergic beta-Antagonists; Aged; Asian People; Aspirin; Atherosclerosis; Calcium Channel Blockers; | 2009 |
[Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; P | 2009 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; D | 2010 |
TP receptor activation and inhibition in atherothrombosis: the paradigm of diabetes mellitus.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Plaque, Atherosclerotic; Platele | 2011 |
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Drug Resistance; Female; Gastrointes | 2010 |
[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
Topics: Abbreviations as Topic; Aspirin; Atherosclerosis; Blood Platelets; Clinical Trials as Topic; Diabete | 2010 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationship, Drug; Hemorrha | 2011 |
Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Evidence-Based Medi | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; H | 2010 |
Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cilostazol; Clopidogrel; Diabetes Complicati | 2010 |
Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Compli | 2012 |
[Antiaggregation: aspirin].
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Di | 2003 |
Current concepts of cardiovascular diseases in diabetes mellitus.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2003 |
[Primary and secondary prevention of coronary artery disease].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2003 |
Epidemiology of pancreatic cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cholecystectomy; Cholelithiasis; Chronic Disease; | 2004 |
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspir | 2004 |
Prevention of cardiovascular disease: an evidence-based clinical aid 2004.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiova | 2004 |
[Acetylsalicylic acid for the primary prevention of cardiovascular disease in diabetic patients].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; P | 2004 |
Prevention of cardiovascular complications of diabetes mellitus by aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2004 |
[Cardiovascular risk in diabetes--diagnostic and therapeutic aspects].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Mon | 2004 |
Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Diabetes Complications; | 2005 |
Secondary prevention of recurrent stroke.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetes Complications; Endarterectomy; Endarterecto | 2005 |
Multidimensional pharmacologic strategies for diabetes.
Topics: Adult; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspir | 2005 |
Protection against glycation and similar post-translational modifications of proteins.
Topics: Aspirin; Carbohydrates; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced; | 2006 |
[Aspirin therapy for cardiovascular prevention in the diabetic patient: what have we learned from the evidence?].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors | 2006 |
The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Damage, | 2006 |
[Coronary heart disease in patients with diabetes mellitus].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarke | 2006 |
[Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Dyslipidemias; Humans; Hy | 2006 |
[Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Insulin Resistance; Male; | 2006 |
Antiplatelet therapy for primary prevention in diabetes.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diab | 2006 |
[Stents in interventional cardiology].
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clop | 2007 |
[Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Cardiovascular Diseases; Chemotherapy, Adjuv | 2007 |
Quality indicators for the care of diabetes mellitus in vulnerable elders.
Topics: Aged; Aspirin; Diabetes Complications; Diabetes Mellitus; Evidence-Based Medicine; Frail Elderly; Gl | 2007 |
[Unrecognized myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aging; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme In | 2007 |
[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].
Topics: Aspirin; Cardiovascular Diseases; Chemoprevention; Diabetes Complications; Drug Resistance; Humans; | 2007 |
[Peripheral arterial disease--an underappreciated clinical problem].
Topics: Age Factors; Aged; Ankle; Aspirin; Atherosclerosis; Brachial Artery; Diabetes Complications; Dyslipi | 2008 |
The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progres | 2008 |
Primary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Contraceptives, Oral; Diabetes Complications; Diet; Estrogen Rep | 1995 |
Stroke prevention.
Topics: Alcohol Drinking; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1995 |
Diabetes and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Diabetes Complications; Humans; Risk Factors | 1993 |
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Atrial Fibri | 1996 |
Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
Aspirin therapy in diabetes.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Humans | 1997 |
[Intervention in risk factors and protection of target organs].
Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Est | 1997 |
Managing the diabetic patient with acute myocardial infarction.
Topics: Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Humans; Myocardial Infarction; Ri | 1998 |
Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 1998 |
Coronary artery disease in women.
Topics: Adult; Age Factors; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin-Converting En | 1998 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
How to improve the cardiac prognosis for diabetes.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1999 |
Royal College of Physicians of Edinburgh Consensus Conference on lipid lowering to prevent vascular events 17 & 18 March 1999.
Topics: Adult; Aged; Aspirin; Cholesterol; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis | 1999 |
Diabetes and myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Huma | 1999 |
[Antithrombotic therapy for stroke prevention in patients with atrial fibrillation].
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Diabetes Compli | 2000 |
[Treatment of diabetic patients with ischaemic heart disease].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 2000 |
Other drug treatments: the evidence.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspi | 2000 |
Managing myocardial infarction in the diabetic patient.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 2000 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2000 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
[Platelet function inhibitors as a way of arterial thrombosis prevention in the diabetic].
Topics: Aspirin; Diabetes Complications; Diabetic Angiopathies; France; Humans; Platelet Aggregation Inhibit | 2001 |
What is the relevance of the HOPE study in general practice?
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic | 2001 |
Risk factors and primary prevention of ischemic heart disease in women.
Topics: Alcohol Drinking; Antioxidants; Aspirin; Diabetes Complications; Exercise; Female; Humans; Hyperlipi | 2001 |
Do acetylsalicylic acid and other antiplatelet drugs prevent preeclampsia?
Topics: Aspirin; Autoimmune Diseases; Clinical Trials as Topic; Diabetes Complications; Dose-Response Relati | 2001 |
Aspirin intolerance--a review.
Topics: Adolescent; Adult; Age Factors; Aged; Angioedema; Aspirin; Asthma; Blood Coagulation; Child; Child, | 1977 |
Analgesic nephropathy and the renal concentrating mechanism.
Topics: Aging; Amyloidosis; Analgesics; Anemia, Sickle Cell; Animals; Aspirin; Calcinosis; Dehydration; Diab | 1977 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
[Ototoxic factors requiring consideration in the diagnosis of occupational hearing loss].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Aspirin; Bacterial Infections; Carbon Disulfide; Carbo | 1985 |
35 trials available for aspirin and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial.
Topics: Adult; Ascorbic Acid; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, T | 2017 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Dietary Su | 2018 |
Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.
Topics: Adult; Age Factors; Aged; Asian People; Aspirin; Cardiovascular Diseases; Diabetes Complications; Fe | 2013 |
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl | 2013 |
Feasibility and impact of implementing a private care system's diabetes quality improvement intervention in the safety net: a cluster-randomized trial.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; C | 2015 |
The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin.
Topics: Aged; Aspirin; Blood Platelets; Cohort Studies; Coronary Artery Disease; Diabetes Complications; Dia | 2015 |
Reporting on the Strategies Needed to Implement Proven Interventions: An Example From a "Real-World" Cross-Setting Implementation Study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Diab | 2016 |
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth | 2016 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Follow-Up Studies; Humans; Male; R | 2017 |
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Topics: Activities of Daily Living; Aged; Aspirin; Cognition; Diabetes Complications; Dose-Response Relation | 2009 |
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete | 2010 |
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 2. Translational research and evidence-based medicine (EBM) in internal medicine in Japan, EBM; 1) How to understand the results of randomized controlled trials for primary
Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Evidence-Based Medicine; Humans; Pro | 2012 |
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi | 2002 |
Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
Topics: Aged; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Fe | 2005 |
Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assis | 2006 |
Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; | 2006 |
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Colla | 2009 |
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
Topics: Aged; Aspirin; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F | 2007 |
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Less benefit from warfarin in diabetics after myocardial infarction?
Topics: Aged; Anticoagulants; Aspirin; Confounding Factors, Epidemiologic; Diabetes Complications; Drug Ther | 2008 |
Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.
Topics: Adult; Aspirin; Diabetes Complications; Diabetic Retinopathy; Follow-Up Studies; Humans; Laser Coagu | 1995 |
Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.
Topics: Adult; Anti-Inflammatory Agents; Aspirin; Blood-Retinal Barrier; Capillary Permeability; Diabetes Co | 1996 |
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Respo | 1997 |
Do intensive blood pressure lowering and low-dose ASA help our hypertensive patients?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1998 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Diabetic retinopathy study results reveal combination therapy beneficial.
Topics: Aspirin; Combined Modality Therapy; Diabetes Complications; Diabetic Retinopathy; Humans; Light Coag | 1990 |
Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Uns
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Diabetes Complications; Disease Progression; Double | 2000 |
Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16.
Topics: Adult; Aspirin; Cataract; Diabetes Complications; Diabetic Retinopathy; Female; Follow-Up Studies; H | 1992 |
European stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Dipyridamole; D | 1992 |
Long-term evaluation of indobufen in peripheral vascular disease.
Topics: Aspirin; Diabetes Complications; Female; Humans; Intermittent Claudication; Isoindoles; Male; Middle | 1991 |
Controlled trial of aspirin in cerebral ischemia: an addendum.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1986 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
[Prevention of postoperative thrombo-embolism with acetylsalicyclic acid (author's transl)].
Topics: Age Factors; Angina Pectoris; Aspirin; Body Weight; Diabetes Complications; Female; Follow-Up Studie | 1974 |
158 other studies available for aspirin and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
[Is Concomitant Therapy with Acetaminophen and Low-dose Aspirin a Risk Factor for CKD Progression? A 6-Year Cohort Study].
Topics: Acetaminophen; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Biomarkers; Creatinine; Diabete | 2020 |
Recommendation of Aspirin-Guide App and Physicians Clinical Decision of Aspirin Use to Prevent CVD Among Diabetic Patients, Is there any Differences?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Cross-Se | 2021 |
Co-morbid risk factors and NSAID use among white and black Americans that predicts overall survival from diagnosed colon cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African American; Cohort Studies; | 2020 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual | 2021 |
The relationship between the level of vitamin D and ruptured intracranial aneurysms.
Topics: Adult; Aged; Aneurysm, Ruptured; Aspirin; Case-Control Studies; Cerebral Angiography; China; Comorbi | 2021 |
Use of Preventive Aspirin Among Older US Adults With and Without Diabetes.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Dia | 2021 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
Associations of Statins and Diabetes with Diagnosis of Ulcerated Cutaneous Melanoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectio | 2017 |
Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Beijing; Blood Glucose; Cholesterol, LDL; Cross-Sectional S | 2018 |
Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Complicati | 2019 |
Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a cross-sectional study.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Complicat | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet | 2013 |
Hyperhomocysteinemia and vascular access thrombosis in hemodialysis patients: a retrospective study.
Topics: Aged; Aspirin; Biomarkers; Chi-Square Distribution; Diabetes Complications; Female; Fibrinolytic Age | 2013 |
Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers.
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Asian People; Aspirin; Diabetes Complications; Diabetes | 2013 |
Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Diabetes Complications; Female; Follow-Up Studies; Humans; Hydroxy | 2014 |
Acetylsalicylic acid protects erectile function in diabetic rats.
Topics: Acetylcholine; Animals; Aspirin; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Experime | 2014 |
Decade-long trends in the characteristics, management and hospital outcomes of diabetic patients with ST-segment elevation myocardial infarction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2014 |
Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
Topics: Age Distribution; Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Diabetes Com | 2014 |
Discrepancies in cardiovascular disease risk calculation affect aspirin use recommendations in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aspirin; Black or African American; Cardiovascular Diseases; Decision Suppo | 2014 |
High dose of aspirin moderates diabetes-induced changes of heart glycogen/glucose metabolism in rats.
Topics: Animals; Aspirin; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Glucose; G | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) randomized trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; C | 2014 |
Analysis of periinterventional complications of intracranial angioplasty and stenting: a single center experience.
Topics: Aged; Angioplasty; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Diabetes Complication | 2014 |
Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; | 2015 |
An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.
Topics: Aged; Aged, 80 and over; American Heart Association; Antihypertensive Agents; Aspirin; Calibration; | 2015 |
Aspirin 'resistance': impact on no-reflow, platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Diabetes Complications; Drug Resistance; Female; Humans; Inf | 2015 |
Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
Topics: Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus; F | 2015 |
Aspirin in the prevention of cardiovascular events in patients with diabetes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Admin | 2016 |
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Glucose; Blood Platelets; Diabetes Complica | 2016 |
Comparison of stent thrombosis, myocardial infarction, and mortality following drug-eluting versus bare-metal stent coronary intervention in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Denmark; Diabetes Complications; Drug-Eluting Stents; Female; Humans; Ma | 2008 |
Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Diabetes Complications; | 2008 |
Diabetes and aspirin: beware of underpowered negative trials.
Topics: Aspirin; Clinical Trials as Topic; Diabetes Complications; Fibrinolytic Agents; Humans; Myocardial I | 2009 |
["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes | 2009 |
[Factors that influence the implementation of the guidelines for aspirin use by diabetic patients in Israel].
Topics: Adult; Aspirin; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Female; Guidelines | 2008 |
[Anti-platelet treatment for all diabetic patients?].
Topics: Aged; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Complications; Female; Hum | 2010 |
Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Gastrointestina | 2009 |
[Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus | 2009 |
Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats.
Topics: Animals; Aspirin; Blood Glucose; Body Weight; Carnosine; Cataract; Diabetes Complications; Drinking | 2009 |
Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2010 |
[Aspirin as primary prevention for diabetic patients].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; P | 2010 |
[Stroke: women have a different risk profile].
Topics: Aspirin; Contraceptive Agents, Female; Diabetes Complications; Education; Exercise; Female; Hormones | 2010 |
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response | 2010 |
Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College
Topics: American Heart Association; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Melli | 2010 |
Aspirin resistance in hemodialysis patients.
Topics: Aspirin; Diabetes Complications; Drug Resistance; Humans; Kidney Failure, Chronic; Platelet Aggregat | 2012 |
On the unfulfilled public health potential of aspirin.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Neoplas | 2010 |
Aspirin for people with diabetes: a misleading inference in a recent meta-analysis?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Meta-Analysis as Topic; Primary Pr | 2010 |
Double jeopardy: pyogenic liver abscess and massive secondary rectal haemorrhage after rubber band ligation of haemorrhoids.
Topics: Aspirin; Diabetes Complications; Enterobacter aerogenes; Enterobacteriaceae Infections; Gastrointest | 2011 |
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
Topics: Aged; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials | 2010 |
Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association(AHA), and an expert consensus
Topics: American Heart Association; Aspirin; Cardiology; Cardiovascular Diseases; Diabetes Complications; Ev | 2010 |
Aspirin in the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Hemorrhage; Humans; Male; Platelet | 2011 |
Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Diab | 2011 |
Genetic associations between fibrinogen and cognitive performance in three Scottish cohorts.
Topics: Aged; Aging; Aspirin; Atherosclerosis; Cognition; Cognition Disorders; Cohort Studies; Cross-Section | 2011 |
Is testing for aspirin response worthwhile in high-risk pregnancy?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Canada; Diabetes Complications; Dose-Respon | 2011 |
Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Diabetes Complicati | 2011 |
Potentiation of aspirin-induced cerebroprotection by minocycline: a therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia.
Topics: Animals; Aspirin; Blood Glucose; Blood-Brain Barrier; Body Weight; Brain; Brain Edema; Capillary Per | 2012 |
Why P is not perfect.
Topics: Aspirin; Bayes Theorem; Cardiovascular Agents; Cardiovascular Diseases; Data Interpretation, Statist | 2012 |
Impact of low-dose aspirin on coronary artery spasm as assessed by intracoronary acetylcholine provocation test in Korean patients.
Topics: Acetylcholine; Age Factors; Aspirin; Coronary Angiography; Coronary Vasospasm; Diabetes Complication | 2012 |
Long-term risk of vascular events after peripheral bypass surgery. A cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Aspirin; Blood | 2012 |
Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
Topics: Animals; Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Platelet Aggregation Inhi | 2012 |
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2012 |
An aspirin a day: the allure (and distraction) of chemoprevention.
Topics: Alcohol Drinking; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin | 2012 |
[The risk factors for colonic diverticular bleeding].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calci | 2012 |
Aspirin for the primary prevention of coronary events.
Topics: Aspirin; Coronary Disease; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; Risk Fac | 2002 |
[Baseline characteristics and management of patients less than 45 years of age hospitalized for acute coronary syndromes: results from the nationwide French PREVENIR 1 and PREVENIR 2 studies].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Angina, Unstable; Angiotensin-Converting Enzyme Inh | 2002 |
Improving aspirin prophylaxis in a primary care diabetic population.
Topics: Aspirin; Cardiovascular Diseases; Data Collection; Diabetes Complications; Drug Utilization; Humans; | 2003 |
Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Case-Control S | 2002 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Guidelines for improving the care of the older person with diabetes mellitus.
Topics: Accidental Falls; Aged; Aspirin; Cognition Disorders; Depression; Diabetes Complications; Diabetes M | 2003 |
Study identifies risk factors for women's coronary heart disease.
Topics: Aspirin; Blood Pressure; Coronary Disease; Diabetes Complications; Ethnicity; Exercise; Female; Huma | 2003 |
[Prevention of myocardial infarct and heart failure in the diabetic].
Topics: Aspirin; Diabetes Complications; Heart Failure; Humans; Myocardial Infarction; Platelet Aggregation | 2003 |
[Diagnosis and therapy of stable angina in Russian Federation (International Study ATP - angina treatment pattern)].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Angiotens | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Primary percutaneous coronary interventions in acute myocardial infarction in diabetic versus non-diabetic patients. In-hospital and long-term results.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Surgical Procedures; Coronary Angiography; | 2003 |
["Economy class syndrome" associated with diabetes and Graves disease].
Topics: Aged; Aircraft; Anticoagulants; Aspirin; Diabetes Complications; Female; Graves Disease; Humans; Pul | 2003 |
A case of frequently recurring amaurosis fugax with atherothrombotic ophthalmic artery occlusion.
Topics: Amaurosis Fugax; Angiography, Digital Subtraction; Arterial Occlusive Diseases; Arteriosclerosis; As | 2004 |
[Cardiovascular risk stratification in general practice].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; Cholesterol; Coronar | 2004 |
[Recommendations for cardiovascular rehabilitation in diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon; Aspirin; Blood Glucose; Cardiov | 2003 |
Consensus statement for the prevention of vascular disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Australia; Diabetes Complications; Diabetes Mellitus; Family Pra | 2004 |
[Management of stroke in a ward of internal medicine. Limits and prospects].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Pharmacoepidemiology; Platelet Agg | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; P | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Humans; Platelet Aggreg | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitu | 2004 |
[Aspirin use in patients with diabetes mellitus].
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitu | 2004 |
Aspirin therapy. Association recommends widespread use.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Male; United States | 2003 |
Factors associated with optic disc hemorrhages in glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Cyclooxygenase Inhibitors; Diabetes Complic | 2004 |
Pattern of drug utilization among hypertensives in a Nigerian teaching hospital.
Topics: Aspirin; Cross-Sectional Studies; Diabetes Complications; Diuretics; Drug Combinations; Drug Interac | 2005 |
[Secondary prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Diabetes Complications; Guideline Adherence; Humans; H | 2004 |
[Characteristic features of the pathogenesis and treatment of coronary heart diseases, heart failure and arterial hypertension in patients with diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Glucose; Calcium Channel Blockers; Clinical Trial | 2005 |
[A new risk score for patients with a normal or non-diagnostic ECG admitted to a chest pain unit].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chest Pain; Coronary Disease; D | 2005 |
Clinical outcomes and left ventricular function in diabetic patients with acute myocardial infarction treated by primary coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Dia | 2005 |
Association between body mass index and CKD in apparently healthy men.
Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Cohort Stu | 2005 |
Aspirin use for the primary prevention of coronary heart disease in older adults.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Coronary Disease; Diabetes Complications; Drug Uti | 2005 |
Is aspirin effective in diabetic patients? Yes.
Topics: Aspirin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Treatment Outcome | 2005 |
Is aspirin effective in diabetic patients? No.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus; Hemorrhage; Humans; Risk Assessment; Treatment F | 2005 |
Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System.
Topics: Adult; Aged; Aspirin; Behavioral Risk Factor Surveillance System; Cardiovascular Diseases; Diabetes | 2006 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
Increased cardiovascular risk associated with diabetes in Dallas County.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Calcium; Cardiovascular Dis | 2006 |
Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus.
Topics: Adult; Aspirin; Cardiovascular Diseases; Causality; Comorbidity; Diabetes Complications; Diabetes Me | 2005 |
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl | 2006 |
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Clopidogrel; Coronary Disease; Diabetes Complic | 2006 |
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases | 2007 |
Susceptibility of the ocular lens to nitric oxide: implications in cataractogenesis.
Topics: Adenosine Triphosphate; Aging; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biological | 2007 |
Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Co | 2007 |
Aspirin resistance and diabetes mellitus.
Topics: Aspirin; Blood Platelets; Diabetes Complications; Diabetic Angiopathies; Drug Resistance; Humans; Pl | 2008 |
Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Diabetes Complications | 2008 |
Is there less benefit from warfarin in diabetics after myocardial infarction? The numbing complexities of assessing anticoagulant and antiplatelet therapy in the diabetic patient.
Topics: Anticoagulants; Aspirin; Diabetes Complications; Drug Therapy, Combination; Humans; Meta-Analysis as | 2008 |
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Arachidonic Acid; Aspirin; Body Mass Index; Cell Adhesio | 2009 |
Enhanced in vivo platelet activation in diabetes mellitus.
Topics: Adult; Aged; Aging; Aspirin; Blood Platelets; Calcium Channel Blockers; Cardiovascular Diseases; Dia | 1982 |
Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation.
Topics: Animals; Aqueous Humor; Aspirin; Cataract; Crystallins; Diabetes Complications; Galactose; Humans; L | 1983 |
Atherosclerosis in diabetes mellitus.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Diabetes Complications; Diabetes Mellitus; Epoprostenol; | 1981 |
Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Cataract; Diabetes Complications; Female; Humans; Male; Middle | 1981 |
Platelet life-span in diabetics with and without retinopathy.
Topics: Adult; Aspirin; Blood Glucose; Blood Platelets; Cell Survival; Diabetes Complications; Diabetes Mell | 1981 |
Senile cataracts: evidence for acceleration by diabetes and deceleration by salicylate.
Topics: Age Factors; Aged; Aspirin; Cataract; Diabetes Complications; Humans; Middle Aged; Osteoarthritis; T | 1981 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
Is aspirin effective in preventing strokes in diabetic patients?
Topics: Aspirin; Cerebrovascular Disorders; Diabetes Complications; Humans; Ticlopidine | 1993 |
Glycation-induced inactivation of malate dehydrogenase protection by aspirin and a lens molecular chaperone, alpha-crystallin.
Topics: Animals; Aspirin; Carbohydrates; Cataract; Crystallins; Diabetes Complications; Diabetes Mellitus; G | 1996 |
[Atrial fibrillation and apoplexy--risks and prevention].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Controlled Clinical T | 1996 |
Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy?
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Fibrinolytic Agents | 1996 |
Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
Presence and treatment of vascular risk factors in patients with vascular cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspirin; Cognition Disorders; Dementia; Diabetes Complic | 1997 |
[Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments in favor].
Topics: Age Factors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Female; Humans; Hypercholestero | 1996 |
Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie.
Topics: Adult; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Diabetes Complications; | 1997 |
Aspirin therapy in diabetes. American Diabetes Association.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Male | 1997 |
Aspirin therapy in diabetic subjects post-myocardial infarction.
Topics: Aspirin; Diabetes Complications; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 1997 |
Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary | 1998 |
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 1999 |
Comparison of secondary prevention measures after myocardial infarction in subjects with and without diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; | 1999 |
Stroke risk, cholesterol and statins.
Topics: Aged; Aspirin; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 1999 |
Aspirin use and the prevention of acute ischemic cranial nerve palsy.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cranial Nerve Diseases; Crani | 2000 |
Meeting report of the ASPET-Ray Fuller Symposium: insulin resistance in diabetes and hypertension: syndrome X and beyond.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Endot | 2000 |
[One-year follow-up of a population of patients with angina. Factors influencing mortality and occurrence of cardiovascular events. Results of the ELAN study].
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angina Pectoris; Anti-Infl | 2000 |
Aspirin therapy in diabetes is underutilized.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Humans | 2001 |
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe | 2001 |
Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure | 2001 |
[Arterial hypertension - the specific case].
Topics: Aspirin; Carotid Artery, Internal; Carotid Stenosis; Diabetes Complications; Diet; Exercise; Follow- | 2001 |
Acetaminophen, aspirin, and chronic renal failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Cas | 2001 |
[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Diabetes | 2001 |
Acute myocardial infarction in the young--The University of Michigan experience.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Anticoagulants; Aspirin; Coronary Artery B | 2002 |
Oral anticoagulation for acute coronary syndromes.
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Clopi | 2002 |
Aspirin therapy in diabetes.
Topics: Aspirin; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Humans; Platelet Aggre | 2000 |
Serum triglyceride and cholesterol levels and lipid electrophoretic patterns in intrinsic and extrinsic allergic states.
Topics: Adult; Aspirin; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Cholesterol; Diabetes Complicati | 1977 |
[Which anti-inflammatory and which analgesic agents should one select for diabetics?].
Topics: Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Diabetes Complications; Diabet | 1978 |
Treatment of diabetic necrobiosis with aspirin or dipyridamole.
Topics: Adolescent; Adult; Animals; Aspirin; Diabetes Complications; Diabetes Mellitus, Type 1; Dipyridamole | 1978 |
[Problems of arteriosclerosis epidemiology. Analysis of risk factors with a view to a possible therapy].
Topics: Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Arteriosclerosis; Aspirin; Blood | 1976 |
[Influence of genetic factors, of ulcerogenic drugs and of a sound disease on both the incidence and characteristics of peptic ulcer].
Topics: Adrenal Cortex Hormones; Aspirin; Cardiovascular Diseases; Diabetes Complications; Humans; Kidney Fa | 1976 |
Prevention of stroke.
Topics: Age Factors; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Auscultation; Cerebral Angiograph | 1975 |
Intrinsic asthma associated with diabetes mellitus; abnormal vascular response and glucose tolerance tests.
Topics: Aspirin; Asthma; Blood Coagulation Tests; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Diabet | 1975 |
Diabetes mellitus and insulin in an aspirin sensitive asthmatic.
Topics: Aspirin; Asthma; Azo Compounds; Benzenesulfonates; Coloring Agents; Diabetes Complications; Diabetes | 1976 |
[Cardiovascular risk factors and restenosis after PTCA].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 1992 |
Ischemic stroke. How to keep the first one from happening.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; I | 1991 |
Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; C | 1990 |
Do aspirin-like analgesics protect against cataract? A case-control study.
Topics: Acetaminophen; Aged; Analgesics; Aspirin; Cataract; Diabetes Complications; Epidemiologic Methods; F | 1986 |
Non-enzymatic acetylation of proteins by aspirin as protection against the secondary complications of diabetes mellitus.
Topics: Acetylation; Aspirin; Diabetes Complications; Diabetes Mellitus; Glycosylation; Humans; In Vitro Tec | 1986 |
The treatment of pulmonary embolism.
Topics: Adult; Aspirin; Blood Coagulation Tests; Cholelithiasis; Diabetes Complications; Female; Heparin; Hu | 1973 |
Tween 80 exacerbated intrinsic rhinitis and asthma in non-aspirin-sensitive patients.
Topics: Aspirin; Asthma; Blood Vessels; Chemical Phenomena; Chemistry; Cholestyramine Resin; Diabetes Compli | 1974 |
Cystitis emphysematosa.
Topics: Adult; Aspirin; Cephalexin; Cystitis; Cystoscopy; Diabetes Complications; Diabetes Mellitus; Diet, D | 1974 |
Inhibition of glucose oxidase paper tests by reducing metabolites.
Topics: Adult; Alkaptonuria; Aspirin; Diabetes Complications; Diabetes Mellitus; Dihydroxyphenylalanine; Fal | 1970 |
The aetiology of renal medullary necrosis: a survey of adult cases in Liverpool.
Topics: Adult; Aged; Aspirin; Codeine; Diabetes Complications; England; Female; Humans; Kidney; Kidney Papil | 1970 |
Medical grand rounds from the University of Alabama Medical Center.
Topics: Adult; Anemia, Sickle Cell; Animals; Arthritis, Rheumatoid; Aspirin; Biopsy; Blood Urea Nitrogen; Di | 1969 |